tiprankstipranks
Trending News
More News >

Mirum Pharmaceuticals price target raised to $77 from $73 at Raymond James

Raymond James analyst Ryan Deschner raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $77 from $73 and keeps a Strong Buy rating on the shares. The price target increase is driven by bile acid portfolio and Livmarli net sales in addition to raised guidance for fiscal 2025, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue